Rare but achievable – factors for successfully navigating rare oncology trials

Medicon Valley Alliance and Worldwide Clinical Trials are pleased to invite you to a Good Morning Meeting on the 24th of May in Copenhagen focusing on Rare but achievable – factors for successfully navigating rare oncology trials.

Conducting clinical trials in rare oncology populations can have its challenges. This event – designed for C-level Executives, Heads of Development, Pre-clinical & Clinical Operations leadership – will be focused on solutions and strategies to support the design and conduct of clinical trials in rare oncology, applicable to other rare indications. In addition to the presentation and case studies, attendees will be able to network with peers and industry thought leaders dedicated to bringing critical new therapies to cancer patients in need.

Worldwide Clinical Trials is a leading global, full-service contract research organization (CRO) that specializes in delivering personalized clinical trial solutions for biotechnology and pharmaceutical customers, regardless of the size or project complexity. Our therapeutically dedicated professionals are accessible throughout each program to help navigate the rapidly evolving clinical development landscape and problem solve when challenges arise. We customize each project team with the right combination of phase and indication specific expertise, collaboration, and passion. At Worldwide, we are united in cause with our customers to improve the lives of patients through new, innovative therapies.

Key learning objectives:

• Adaptive trial design concepts and considerations
• Optimising patient engagement
• Site selection strategies

Date: Wednesday, 24th of May, 2023
Time: 8:30 – 10:00 CET
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Meeting room: Auditorium

SIGN UP

Program

Speakers​​

Matt Cooper, Therapeutic Strategy Lead, Oncology at Worldwide Clinical Trials Matt has been involved in clinical research for over 25 years in the life sciences industry, the NHS, and UK National Research Networks. As Executive Director, Therapeutic Strategy Lead in the Oncology franchise Matt applies his extensive clinical trials background and understanding of business considerations to anticipate challenges and mitigate risk, while delivering high-quality results to our sponsor partners. Matt gained a PhD in molecular virology and conducted post doc research using herpes viruses as gene therapy vectors. He joined AstraZeneca UK as a Clinical Research Scientist and then Study Manager, conducting phase II and III studies in a variety of therapy areas including oncology. Matt returned to NHS/ academia to establish a Clinical Trials Unit in an NHS hospital. Matt joined the National Cancer Research Network as Assistant Director providing strategic review of the portfolio of studies and methods to deliver them. He was also influential in developing the first alliances between industry and researchers to explore innovative uses for new oncology compounds in phase I & II studies. Matt became Executive Director of the National Institute for Health Research (NIHR) Clinical Research Network, the clinical research delivery arm of the National Health Service (NHS) developing sites and key opinion leaders and during his time doubled the number of commercial trials conducted in the NHS by engaging with Sponsors and CROs across the world.

Sandra Griffin, Executive Director, Project Management, Oncology Sandra has been involved in clinical research with both CROs and Pharma for more than 27 years, with over 15 years project management experience in Oncology clinical studies, she has overseen successful performance and delivery of clinical programs coupled with developing strong client relationships and trusted business partnerships. Sandra began her career in research in the laboratory performing diagnostic and clinical assay analysis, whilst also coordinating central laboratory vendor participation in clinical studies after which she became a CRA and progressed her career through clinical operation and global project management roles in Oncology. Working in both early and late phase registrational programs.  Also, more recently focusing on early phase biotech studies for both liquid and solid tumor types encompassing dose escalation/expansion, cohort management and immuno-oncology studies. She has had particular focus in: Solid Tumors – Breast, Colorectal, Prostate, Lung Cancer (Non-Small Cell Lung Cancer), Thyroid, Melanoma,(phase I, II, III); Hematologic Malignancies – Non-Hodgkins Lymphoma, Follicular Lymphoma, Multiple Myeloma; Hemophilia, Paroxysmal Nocturnal Hemoglobinuria, Myelofibrosis (phase I, II, III).Sandra’s passion and drive lies with overseeing successful delivery of a project. Fundamentally with strong cross functional team communication through experienced project leadership. Having the right team at the right time in a study lifecycle aide’s good relationships, performance and flexibility to ensure solutions and delivery are met.

Organized by	In collaboration with